SR9186

SR9186 (ML368) is a selective CYP3A4 inhibitor with IC50 values of 9, 4, and 38 nM for Midazolam → 1'-hydroxymidazolam, Testosterone → 6β-hydroxytestosterone, and Vincristine → Vincristine M1, respectively. SR-9186 inhibits the development of hepatic-stage P. falciparum and blocks ivermectin metabolism. SR-9186 can be used in breast cancer research[1][2].

Product Specifications

CAS Number

[1361414-26-7]

Product Name Alternative

ML368

UNSPSC

12352005

Target

Cytochrome P450; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/sr9186.html

Purity

98.06

Solubility

DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC=C(C2=C3C(NC=N3)=NC=C2)C=C1)NC4=CC=C(C5=CC=C(C#N)C=C5)C=C4

Molecular Formula

C26H18N6O

Molecular Weight

430.46

References & Citations

[1]Xiaohai Li, et al. Discovery of a highly selective CYP3A4 inhibitor suitable for reaction phenotyping studies and differentiation of CYP3A4 and CYP3A5. Drug Metab Dispos. 2012 Sep;40 (9) :1803-9.|[2]Towles JK, et al. Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib. Drug Metab Dispos. 2016 Oct;44 (10) :1584-97.